التفاصيل البيبلوغرافية
| العنوان: |
The impact of interval between primary cytoreductive surgery with bowel resection and initiation of adjuvant chemotherapy on survival of women with advanced ovarian cancer: a multicenter cohort study. |
| المؤلفون: |
Yoo-Young Lee1, Soyoun Rachel Kim2, Kollara, Alexandra3, Brown, Theodore3,4, May, Taymaa2,4 taymaa.may@uhn.ca |
| المصدر: |
Journal of Gynecologic Oncology. Nov2022, Vol. 33 Issue 6, p1-10. 10p. |
| مصطلحات موضوعية: |
*ADJUVANT chemotherapy, *CYTOREDUCTIVE surgery, *OVARIAN cancer, *SURGICAL excision, *LARGE intestine |
| مصطلحات جغرافية: |
TORONTO (Ont.), SEOUL (Korea) |
| مستخلص: |
Objective: Our aim was to determine if the time interval between bowel resection and initiation of adjuvant chemotherapy impacts survival in advanced ovarian cancers. Methods: This was a retrospective cohort study using data from two cancer centers, Princess Margaret Cancer Centre in Toronto, Ontario, Canada and Samsung Comprehensive Cancer Center in Seoul, South Korea. Patients with International Federation of Gynecology and Obstetrics (FIGO) stage III or IV ovarian cancer that underwent large bowel resection during primary cytoreductive surgery (PCS) were included. Results: Ninety-one women were eligible of which the majority (90.1%) were diagnosed with high-grade serous cancer. The median interval from PCS to chemotherapy for all patients was 21 days (7-86 days). Patients were stratified into 3 groups: 1) Interval =14 days, 32 (35.2%) patients; 2) Interval between 15-28 days, 27 (29.6%) patients; and 3) Interval between 29-90 days, 32 (35.2%) patients. Surgical procedures and postoperative outcomes were similar between groups. Multivariate analysis indicated that PCS to chemotherapy interval of 2-4 weeks, younger age, and completion of 4 or more adjuvant chemotherapy cycles were independent prognostic factors of favorable overall survival. Conclusion: Initiation of adjuvant chemotherapy between 2 to 4 weeks after PCS with bowel resection may improve survival outcomes in women with advanced ovarian cancer by maximizing the benefit of PCS plus adjuvant chemotherapy. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
Full Text Finder